[1] Karlsen TH, Sheron N, Zelber-Sagi S, et al.The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality . Lancet (London, England), 2022, 399(10319): 61-116.
[2] Angulo P, Batts KP, Therneau TM, et al.Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis . Hepatology, 1999, 29(3): 644-647.
[3] Harms MH, Lammers WJ, Thorburn D, et al.Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome . Am J Gastroenterol, 2018, 113(2): 254-264.
[4] Cheung AC, Lammers WJ, Murillo Perez CF, et al.Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis . Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, 17(10): 2076-2084.e2.
[5] Beuers U, Trauner M, Jansen P, et al.New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond . J Hepatol, 2015, 62(1 Suppl): S25-37.
[6] Zollner G, Trauner M.Nuclear receptors as therapeutic targets in cholestatic liver diseases . British journal of pharmacology, 2009, 156(1): 7-27.
[7] Wang YD, Chen WD, Wang M, et al.Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response . Hepatology, 2008, 48(5): 1632-1643.
[8] Kjærgaard K, Frisch K, Sørensen M, et al.Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis . J Hepatol, 2021, 74(1): 58-65.
[9] Baghdasaryan A, Claudel T, Gumhold J, et al.Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO3- output . Hepatology, 2011, 54(4): 1303-1312.
[10] Gege C, Hambruch E, Hambruch N, et al.Nonsteroidal FXR Ligands: Current Status and Clinical Applications . Handb Exp Pharmacol, 2019, 256:167-205.
[11] Degirolamo C, Sabbà C, Moschetta A.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 . Nat Rev Drug discov, 2016, 15(1): 51-69.
[12] Luo J, Ko B, Elliott M, et al.A nontumorigenic variant of FGF19 treats cholestatic liver diseases . Science translational medicine, 2014, 6(247): 247ra100.
[13] Ghonem NS, Assis DN, Boyer JL.Fibrates and cholestasis . Hepatology, 2015, 62(2): 635-43.
[14] Liu Y, Colby JK, Zuo X, et al.The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor . Int J Mol Sci, 2018, 19(11):3339
[15] Rubenstrunk A, Hanf R, Hum DW, et al.Safety issues and prospects for future generations of PPAR modulators . Biochimica et biophysica acta, 2007, 1771(8): 1065-1081.
[16] Arenas F, Hervias I, Uriz M, et al.Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells . J Clin Invest, 2008, 118(2): 695-709.
[17] Yoon YB, Hagey LR, Hofmann AF, et al.Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents . Gastroenterology, 1986, 90(4): 837-852.
[18] Halilbasic E, Fiorotto R, Fickert P, et al.Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice . Hepatology, 2009, 49(6): 1972-1981.
[19] Moustafa T, Fickert P, Magnes C, et al.Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury . Gastroenterology, 2012, 142(1): 140-151.e12.
[20] Aoyama T, Paik YH, Watanabe S, et al.Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent . Hepatology, 2012, 56(6): 2316-2327.
[21] Kuiper EM, van Erpecum KJ, Beuers U, et al.The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial . Hepatology, 2010, 52(4): 1334-1340.
[22] Hofmann AF. Inappropriate ileal conservation of bile acids in cholestatic liver disease: homeostasis gone awry . Gut, 2003, 52(9): 1239-1241.
[23] Yu H, Zhao T, Liu S, et al.MRGPRX4 is a bile acid receptor for human cholestatic itch . eLife, 2019, 8:e48431.
[24] Johansson M, Str?mberg J, Ragagnin G, et al.GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo . J Steroid Biochem Mol Biol, 2016, 160:98-105.
[25] Montagnese S, Lauridsen M, Vilstrup H, et al.A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy . J Hepatol, 2021, 75(1): 98-107. |
